Efficacy and safety of omalizumab combined with allergen immunotherapy in children with moderate to severe allergic asthma

Abstract

Omalizumab enables children who are intolerant to AIT to initiate AIT successfully. Combination therapy better improves asthma and rhinitis symptoms, FeNO, and lung function compared to single SCIT or omalizumab treatment. Combination therapy reduces the incidence of adverse reactions during the initial phase of SCIT and enhances its safety.

Keywords: allergen immunotherapy; combination therapy; efficacy; moderate to severe allergic asthma in children; omalizumab; safety.